Market research
IPA.V ImmunoPrecise Antibodies Ltd
V CAD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 162M
- P/E ratio
- Not available
- Analyst target
- 12
- Dividend yield
- 0.0%
- Beta
- 0.3
Profile
Company facts
- Exchange
- V
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- CA45257F2008
- Market cap
- 162M
- P/E ratio
- Not available
- Analyst target
- 12
- Dividend yield
- 0.0%
- Beta
- 0.3
About
About ImmunoPrecise Antibodies Ltd
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its contract research organization services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the IPA.V discussion.
5 years, 5 months ago
ImmunoPrecise Antibodies Ltd is currently in a long term downtrend where the price is trading 41.9% below its 200 day moving average.
From a valuation standpoint, the stock is 98.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 13.8.
ImmunoPrecise Antibodies Ltd's total revenue rose by 11.9% to $5M since the same quarter in the previous year.
Its net income has dropped by 106.8% to $-1M since the same quarter in the previous year.
Finally, its free cash flow fell by 245.3% to $-1M since the same quarter in the previous year.
Based on the above factors, ImmunoPrecise Antibodies Ltd gets an overall score of 2/5.